Education
About Us
Working with TipRanks
Follow Us
Nova Eye Medical (ELXMF)
OTHER OTC:ELXMF
ELXMF Stock Chart & Stats
$0.25
$0.00(0.00%)
At close: 4:00 PM EDT
$0.25
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.10 - $0.25
Previous CloseN/A
Volume100.00
Average Volume (3M)0.00
Market Cap
$32.03M
Enterprise Value$46.38M
Total Cash (Recent Filing)$5.05M
Total Debt (Recent Filing)$3.02M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding284,833,280
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.43
Price to Sales (P/S)0.93
P/FCF Ratio-4.14
Enterprise Value/Market Cap1.45
Enterprise Value/Revenue1.58
Enterprise Value/Gross Profit2.46
Enterprise Value/Ebitda-6.90
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Product PortfolioNova Eye's focus on surgical devices and consumables positions it in a specialized, procedure-driven market where products are consumed repeatedly and are integral to clinical workflows. This creates durable, recurring demand and strengthens long-term customer relationships and product stickiness.
Low Financial LeverageA low debt-to-equity ratio provides financial flexibility to fund R&D, manufacturing scale-up, and commercialization without heavy interest burdens. In capital-intensive medtech, manageable leverage reduces default risk and supports strategic investment during multi-year product cycles.
Sustained Revenue GrowthConsistent top-line growth demonstrates market acceptance and increasing adoption of products. A growing revenue base supports operating scale and provides a platform to invest in margin recovery, distribution expansion, and new product development over the medium term.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows indicate ongoing cash burn that limits reinvestment and forces dependence on external financing or equity dilution. Over months this constrains ability to scale manufacturing, commercialize new products, and sustain operations without funding.
Sharply Declining Gross MarginA large fall in gross margin signals rising cost of goods sold, adverse mix, or pricing pressure. Margin compression reduces operating leverage, making profitability harder to achieve and undermining free cash flow recovery unless cost structure or pricing is corrected.
Ongoing Losses And Negative ROEContinued net losses and negative return on equity mean the company is not generating shareholder returns and is consuming capital. Without a clear, sustained path to profitability, the business may face prolonged funding needs and weaker capacity to invest in strategic growth initiatives.
Nova Eye Medical News
ELXMF FAQ
What was Nova Eye Medical’s price range in the past 12 months?
Nova Eye Medical lowest stock price was $0.10 and its highest was $0.25 in the past 12 months.
What is Nova Eye Medical’s market cap?
Nova Eye Medical’s market cap is $32.03M.
When is Nova Eye Medical’s upcoming earnings report date?
Nova Eye Medical’s upcoming earnings report date is Aug 27, 2026 which is in 185 days.
How were Nova Eye Medical’s earnings last quarter?
Currently, no data Available
Is Nova Eye Medical overvalued?
According to Wall Street analysts Nova Eye Medical’s price is currently Overvalued.
Does Nova Eye Medical pay dividends?
Nova Eye Medical pays a Notavailable dividend of $0.294 which represents an annual dividend yield of N/A. See more information on Nova Eye Medical dividends here
What is Nova Eye Medical’s EPS estimate?
Nova Eye Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nova Eye Medical have?
Nova Eye Medical has 284,833,280 shares outstanding.
What happened to Nova Eye Medical’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nova Eye Medical?
Currently, no hedge funds are holding shares in ELXMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nova Eye Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
ELXMF Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $7.7K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
-44.16%
Trailing 12-Months
Asset Growth
-12.96%
Trailing 12-Months
Company Description
Nova Eye Medical
Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services surgical devices for the treatment of glaucoma. The company offers iTrack, a surgical system for the reduction in intraocular pressure (IOP) in adult patients with open-angle glaucoma; iTrack Advance, a natural ocular drainage system; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. It operates in Australia, the United States, Europe, the Asia Pacific, and internationally. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was founded in 1985 and is headquartered in Kent Town, Australia.
Technical Analysis
Compumedics Limited
―
Cyclopharm Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―
Ownership Overview
Options Prices
Currently, No data available
---